Quince Therapeutics, Inc.
QNCX
$3.69
$0.319.02%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.28M | 3.34M | 4.79M | 1.78M | 3.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.36M | 9.90M | 12.93M | 7.61M | 8.55M |
| Operating Income | -11.36M | -9.90M | -12.93M | -7.61M | -8.55M |
| Income Before Tax | -13.49M | -15.98M | -14.98M | -12.45M | -5.48M |
| Income Tax Expenses | -46.00K | 67.00K | 47.00K | 7.00K | 13.00K |
| Earnings from Continuing Operations | -13.44M | -16.05M | -15.03M | -12.46M | -5.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.44M | -16.05M | -15.03M | -12.46M | -5.49M |
| EBIT | -11.36M | -9.90M | -12.93M | -7.61M | -8.55M |
| EBITDA | -11.33M | -9.86M | -12.90M | -7.59M | -8.46M |
| EPS Basic | -0.25 | -0.34 | -0.34 | -0.28 | -0.13 |
| Normalized Basic EPS | -0.13 | -0.20 | -0.18 | -0.11 | -0.11 |
| EPS Diluted | -0.25 | -0.34 | -0.34 | -0.28 | -0.13 |
| Normalized Diluted EPS | -0.13 | -0.20 | -0.18 | -0.11 | -0.11 |
| Average Basic Shares Outstanding | 53.95M | 46.69M | 43.94M | 43.78M | 43.16M |
| Average Diluted Shares Outstanding | 53.95M | 46.69M | 43.94M | 43.78M | 43.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |